News
ANEB
0.450
+25.00%
0.090
Weekly Report: what happened at ANEB last week (0223-0227)?
Weekly Report · 1d ago
Weekly Report: what happened at ANEB last week (0216-0220)?
Weekly Report · 02/23 09:36
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 02/19 12:05
Weekly Report: what happened at ANEB last week (0209-0213)?
Weekly Report · 02/16 09:36
Anebulo Pharmaceuticals Q2 EPS $(0.05) Beats $(0.13) Estimate
Benzinga · 02/12 21:57
Anebulo Pharmaceuticals GAAP EPS of -$0.05
Seeking Alpha · 02/12 21:49
Anebulo Pharma posts Q2 net loss of USD 2.0 million, down 20 percent
Reuters · 02/12 21:49
*Anebulo Pharmaceuticals 2Q Loss/Shr 5c >ANEB
Dow Jones · 02/12 21:44
Anebulo Pharmaceuticals Q2 net loss narrows
Reuters · 02/12 21:27
Anebulo Pharmaceuticals Announces Voluntary Delisting From Nasdaq
Benzinga · 02/12 21:19
ANEBULO PHARMACEUTICALS INC - BOARD APPROVES VOLUNTARY DELISTING FROM NASDAQ - SEC FILING
Reuters · 02/12 21:17
ANEBULO PHARMACEUTICALS REPORTS SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS AND RECENT UPDATES
Reuters · 02/12 21:15
ANEBULO PHARMACEUTICALS, INC. Q2 EPS USD -0.05
Reuters · 02/12 21:15
Press Release: Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates
Dow Jones · 02/12 21:15
Press Release: Anebulo Pharmaceuticals Reports -2-
Dow Jones · 02/12 21:15
Weekly Report: what happened at ANEB last week (0202-0206)?
Weekly Report · 02/09 09:37
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 02/06 17:05
More
Webull provides a variety of real-time ANEB stock news. You can receive the latest news about Anebulo Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ANEB
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. It is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.